| -0.16 / -3.71%|
The 5 analysts offering 12-month price forecasts for Protalix Biotherapeutics Inc have a median target of 6.00, with a high estimate of 8.00 and a low estimate of 4.50. The median estimate represents a +44.58% increase from the last price of 4.15.
The current consensus among 6 polled investment analysts is to Hold stock in Protalix Biotherapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.